Menu
Oncimmune
Oncimmune has developed a powerful new approach to the early diagnosis of primary cancer, cancer recurrence and the clinical management of cancer.
Healthcare: Diagnostics – cancer
School of Medicine
Profile
Oncimmune has developed a powerful new approach to the early diagnosis of primary cancer, cancer recurrence and the clinical management of cancer.
The technology is based on serum assays that detect auto-antibody formation to known cancer antigens with the clinical utility of early diagnosis of cancer.
This breakthrough is currently applied to lung cancer through the development of a blood test EarlyCDT®, but will be extended to the detection of other common cancers such as breast, colorectal, ovarian and prostate.
The company is based in customised laboratory and office space at Nottingham City Hospital, and began trading on AIM in May 2016.
News and press releases
Our sale of shares represents a significant return on our original investment in Oncimmune and the company is an exemplar of what can be done when a technology is successfully spun out from the University of Nottingham. It has been a pleasure to see Oncimmune grow into a leading early cancer detection company that is already saving lives and is on track to save many more. We look to the future with confidence as the company has the management and strategy in place to deliver value and we are delighted to retain a significant shareholding
Dr Andrew Naylor
Chief executive – Nottingham Technology Ventures
@OncimmuneECDT on Twitter
At #BIOEurope, looking forward to partnering meetings to promote @OncimmuneECDT's SeroTag platform for profiling autoantibodies in immuno-oncology and autoimmune diseases. @BioPartner
Come see the UK delegation @BIOEurope and see who's attending from the UK at https://t.co/oHaN8wjIXn @nanomerics @OBN_UK @OncimmuneECDT @Oppilotech @OxfordBiomedica @OxStem @TeamPhastar @ShieldTx @scotent @therakind @BIA_UK @tradegovuk
#PebmondAssociates, #Pneumagen
We're working in collaboration with @Roy_Castle_Lung to raise awareness during
#LungCancerAwarenessMonth
It’s vital we treat people who have lung cancer as we would anyone else. #FollowMyLead and let’s give patients the support they need: https://t.co/PaooawgEbb
Austria finally implements indoor smoking ban after a decade-long debate. #LCSM
The world’s most livable city is a smoker’s paradise
Austria — including its capital Vienna — finally gets a smoking ban on Friday.
www.vox.com
"As the first company to provide four best-in-class diagnostic tests for patients in lung cancer, Biodesix has demonstrated its commitment to helping physicians and their patients navigate lung cancer therapy decisions."
Congratulations to our US partner @BiodesixInc
Latest News from Business Wire on Twitter
“Biodesix Named Company of the Year by Colorado BioScience Association https://t.co/3UrJcQ7AB5”
twitter.com
November is Lung Cancer Awareness Month. Every year over 47,000 are diagnosed with lung cancer. For information and support visit: https://t.co/FoetyuqwbI
Thank you to our friends and partners @TASC_TCTU for your continued support #lungcancer #lungcancerscreening #lungscreening #detectcancerearly
Tayside Clinical Trials Unit on Twitter
“The Times Magazine has published an article on the early detection of lung cancer, based on the TCTU supported ECLS study! 🔬🧬👨🔬 ...
twitter.com
Delighted to see the positive results of our ECLS trial acknowledged in @MelanieGLee's presentation at the @ELRIG_UK Drug Discovery meeting in Liverpool yesterday. #ELRIG @lifearc1 #lungcancer #lungscreening #lungcancerscreening #detectcancerearly
LGC in partnership with ATCC on Twitter
“Great to hear from the CEO of @lifearc1, @MelanieGLee, who shared her interesting work on predicting #Cancer development years before tumours a...
twitter.com
Gallery
